Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy

• Authors: Shiny Nair, Yale University; Noffar Bar, Yale University; Mina L Xu, Yale University; Madhav Dhodapkar, Emory University; Pramod K Mistry, Yale University
• Journal Title: MOLECULAR GENETICS AND METABOLISM
• Volume: Volume 129, Number 4
• Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE | 2020-04-01, Pages 286-291
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1016/j.ymgme.2020.01.009
• Subjects: Health Sciences, Pathology; Health Sciences, Medicine and Surgery
• Keywords: Science & Technology; Life Sciences & Biomedicine; Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental; Research & Experimental Medicine; Gaucher disease; Glucosylsphingosine; Multiple myeloma; Saposin C; MONOCLONAL GAMMOPATHY; GLUCOSYLCERAMIDE; IMMUNOGLOBULIN; MALIGNANCIES; MYELOMA; RISK

Abstract

In Gaucher disease type 1 (GD1), genetic deficiency of lysosomal glucocerebrosidase results in the accumulation of glucosylceramide and glucosylsphingosine (GlcSph), that underlie chronic lipid-mediated metabolic inflammation. An important age-related phenotype is high risk of monoclonal gammopathy (MG), including multiple myeloma. We identified GlcSph, a pathological lyso-sphingolipid exclusively elevated in GD, as a mediator of B cell activation and as an antigenic target for GD1-associated MG. Saposin C (SapC), is a lipid-binding protein and activator of lysosomal glucocerebrosidase, which when mutated, cause a rare variant of GD. Sera of GD1 patients with MG of diverse immunoglobulin types were compared to GD patients without gammopathy for reactivity against GlcSph and SapC. We show reactivity of clonal immunoglobulin in GD1 to GlcSph but not to SapC. In two patients with GD1 and gammopathy, GlcSph-reduction therapy with eliglustat resulted in reduction in clonal Ig. Together, our data show that GlcSph but not SapC is the antigenic target in GD1-associated MG and that therapy aimed at reducing the levels of immunogenic lipid resulted in reduction of clonal immunoglobulin in vivo.